Axsome Therapeutics has started the FOCUS-2 Phase 3 trial to test solriamfetol as a treatment for children aged 6 to under 12 with ADHD. This randomized, double-blind, placebo-controlled study will enroll about 468 patients to evaluate the drug's efficacy and safety over six weeks. The trial complements a similar ongoing study in adolescents and aims to address the significant impact of ADHD on cognitive function and daily life. Successful results could lead to a new treatment option for pediatric ADHD, a condition affecting millions and associated with high societal costs.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Sodexo has secured a major global contract to provide catering services across more than 130 Meta sites in over 30 countries. This large-scale partnership includes diverse locations such as headquarters, campuses, data centers, and conference centers...
Viasat and BMW Group have successfully demonstrated the first integrated automotive satellite voice call, allowing drivers to make calls directly through the car's infotainment system even in areas without cellular coverage. This advancement, utilizi...
Iran has warned it will retaliate fiercely if the US targets its infrastructure, following President Trump's threat to strike Iranian power plants and bridges next week if negotiations fail. The US recently conducted airstrikes against Iranian milita...
Solana (SOL) maintains its price in the mid-$70 range, supported by several key developments. These include Circle's recent issuance of $500 million in USDC on the Solana network, increasing liquidity and transactional demand. Additionally, instituti...
